

JUN 1 9. 700% BY

Docket No. THR5007USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Steve Gara

Serial No.

10/654,794

Art Unit:

3761

Filed

: September 3, 2003

Examiner: Leslie Deak

For

BLOOD SEPARATION APPARATUS AND METHOD OF USING THE

SAME

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 8, 2006

(Date of Deposit)

Todd F. Volyn
(Name of applicant, assignee, or Registered Representative)

/Todd Volyn/

(Signature)

June 8, 2006

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on May 17, 2005 and July 29, 2005.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

\square In accordance with §1.129(a), this Information
isclosure Statement is being filed in connection with \square the
irst or Second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).

In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

<pre>Statement in Accordance with §1.97(e)</pre>
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth
in §1.17(p).
In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
·
Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Coning of references listed on the attached Harm DEC
Copies of references listed on the attached Form PTO 1449 are enclosed herewith EXCEPT THAT:
1449 are encrosed herewith Except that:
☐ In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
☐ If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
☐ Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2).

There are no listed references which are not in the
English language.
☐ The relevance of those listed references which are
not in the English language is as follows:
<pre>Attached are copies of search report(s) from</pre>
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.
Copies of the references listed on the search
report(s) are included except for those previously cited in an
IDS mailed .
Attached are the following non-published pending
patent applications which may be deemed relevant, which are
listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to
Deposit Account No. 10-0750/THR5007/TFV. This form is
submitted in triplicate.
Respectfully submitted,
/Todd Volyn
Todd F. Volyn
Reg. No. 37,463
Attorney for Applicants
Johnson & Johnson
One Johnson & Johnson Plaza

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-6202 DATED: June 8, 2006 Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2

Application Number	10/654,794
Filing Date	September 3, 2003
First Named Inventor	Gara
Group Art Unit	3761
Examiner Name	Leslie Deak
Attorney Docket Number	THR-5007

U.S. PATENT DOCUMENTS

Evaminer		U.S. Patent Document		Name of Patenton or Applicant	Date of Publication	Pages, Columns, Lines,
Examiner Initials	Cite No. ¹		d Code ² (known)	Name of Patentee or Applicant of Cited Document	of Cited Document mm-dd-yyyy	where relevant passages relevant figures appear
		3,985,442		Khoja et al.	10-19-1976	
		4,111,356	:	Boggs et al.	09-05-1978	
		4,201,525		Brown et al.	05-06-1980	
		4,305,659		Bilstad et al.	12-15-1981	·
		4,309,993		Brown	01-12-1982	
		4,321,919		Edelson	03-30-1982	
		4,333,016		Bilstad et al.	06-01-1982	
		4,374,731		Brown et al.	02-22-1983	
		4,398,908		Edelson	08-16-1983	
		4,425,116		Bilstad et al.	01-10-1984	
		4,428,744		Richard L. Edelson	01-1984	
		4,428,744		Edelson	01-31-1984	
		4,464,166		Edelson	08-07-1984	
	_	4,479,760		Bilstad et al.	10-30-1994	
		4,479,761		Bilstad et al.	10-30-1984	
		4,479,762		Bilstad et al.	10-30-1984	
		4,530,691		Brown	07-23-1985	
		4,605,503		Bilstad et al.	08-122-1986	
		4,680,025		Kruger et al.	07-14-1987	
		4,724,317		Brown et al.	02-09-1988	
		4,834,890		Brown et al.	05-30-1989	
		4,940,543		Brown et al.	07-10-1990	
		5,316,666		Brown et al.	05-31-1994	
		5,945,291		Bolton et al.	08-31-1999	
		6,204,058		Bolton	03-20-2001	
		6,495,366		Briggs	12-17-2002	

JUN 1 2 7006 W

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

Application Number	10/654,794
Filing Date	September 3, 2003
First Named Inventor	Gara
Group Art Unit	3761
Examiner Name	Leslie Deak
Attorney Docket Number	THR-5007

		U.S. Patent Docume	ent			
Examiner Initials	Cite No.1	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		4,895,333		I. Panzani	08-22-1989	
	TT	6,219,584		K.H. Lee	04-17-2001	
		6,709,377	·	J.D. Rochat	03-23-2004	
		5,746,708		Giesler et al	05-05-1998	
		6,234,989	B1	Brierton et al	05-22-2001	

FOREIGN PATENT DOCUMENTS

		Foreign	Patent Documer	nt	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ¹	Office ³	Number⁴ Kir	ndCode⁵	Name of Fateritee of	mm-dd-yyyy	passages or relevant figures appear	T⁵
		EP	0786324		B. Braun Melsungen AG	07-30-1997		
		EP	1066842	A2	Therakos, Inc.	01-10-2001		
		wo	97/36634		Therakos, Inc.	10-09-1997		
		wo	97/36581		McLaughlin	10-09-1997		

Examiner	Date	
Signature	Considered	